10x Genomics, Inc. (TXG) Q3 2025 10-Q Quarterly Report
10x Genomics, Inc. (TXG) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
10x Genomics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New acquisition risk from Scale Biosciences asset acquisition in August 2025 with $20M technology transfer payment due Q1 2026 and up to $30M contingent consideration
- • Material update on patent litigation settlements with Vizgen and Bruker, generating total $94M upfront with gain on settlements boosting first-half 2025 revenues
- • Regulatory advantage from July 2025 OBBBA tax law restoring immediate R&D expense deductibility, reducing income tax expense by $3.3M for nine months ended September 2025
- • Market risk from 37-40% decline in instruments revenue for recent periods offset partially by 1-2% growth in consumables sales impacting near-term sales performance
- • Liquidity risk from operating losses and $1.5B accumulated deficit despite $482M cash balance; potential future funding needs due to cash burn and contingent acquisition payments
10x Genomics, Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$149M
▼ -1.7% YoY▼ -13.8% QoQ
Net Income
-$27M
▲ +23.2% YoY▼ -179.5% QoQ
Gross Margin
67.3%
▼ -284bp YoY▼ -502bp QoQ
Operating Margin
-21.6%
▲ +572bp YoY▼ -3906bp QoQ
Net Margin
-18.4%
▲ +514bp YoY▼ -3841bp QoQ
ROE
-3.5%
Total Assets
$1.0B
EPS (Diluted)
$-0.22
▲ +24.1% YoY▼ -178.6% QoQ
Operating Cash Flow
$43M
▲ +99.7% YoY▲ +144.0% QoQ
Source: XBRL data from 10x Genomics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on 10x Genomics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.